PGDx

Eighty percent of today’s patients aren’t being tested in a window of time that actually makes a difference for their treatment decisions. In order to understand cancer, we need to understand the genomic drivers in order to provide personalized treatments that give patients the best chance at beating the disease. PGDx created the first and only FDA-cleared next generation sequencing assay for compressive tumor profiling. The company is delivering fast, reliable, and comprehensive genomic insights that inform critical treatment decisions and cancer care pathways.